As perioperative EV-pembrolizumab moves into routine bladder cancer care, clinicians discuss the practical challenges of patient selection and multidisciplinary coordination. The conversation explores how providers assess frailty in busy clinics, often relying on simple clinical observations, nutrition status, and patient-reported function when formal geriatric evaluation is not available. The panel also debates the future role of biomarkers such as urinary tumor DNA, noting that while early data are promising, these tools are not yet ready to replace established surveillance methods.
Contributors:
Dr. Petros Grivas is a medical oncologist and professor at the University of Washington and Fred Hutchinson Cancer Center in Seattle.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Ashish Kamat is a urologic oncologist at MD Anderson in Houston, Texas and president of The International Bladder Cancer Group.
Dr. Sia Daneshmand is a professor of urology and oncology at the University of Southern California, Norris Comprehensive Cancer Center.
Dr. Matthew Galsky is a medical oncologist at the Icahn School of Medicine at Mount Sinai.
Dr. Guru Sonpavde is a medical oncologist and the Phase 1 new drug development program Director at the AdventHealth Cancer Institute in Orlando, Florida.